Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
Status:
Active, not recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the efficacy of Pembrolizumab, concomitant with and
following standard of care definitive radiation, for locally advanced squamous cell carcinoma
of the head and neck patients who are not good candidates for Cisplatin.